Calendario›MGNX›Lorigerlimab
Lorigerlimab
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Ensayo de MACROGENICS INC en Platinum-resistant Ovarian Cancer · Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma · Clear Cell Adenocarcinoma of Ovary · Clear Cell Adenocarcinoma of Vulva · Clear Cell Adenocarcinoma of Vagina · Clear Cell Adenocarcinoma of Cervix · Clear Cell Adenocarcinoma of Uterus · Clear Cell Adenocarcinoma of Fallopian Tube · Clear Cell Adenocarcinoma of Peritoneum · Endometrial Cancer (del registro, en inglés).
Más ensayos de: Cáncer de ovario resistente al platino · Cáncer de endometrio.
- Fase
- Fase 2
- Estado
- Reclutando pacientes
- Participantes
- 80
- Centros
- 16
- Fin del objetivo primario
- jul 2027
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en may 2025.
Qué mide
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigator (Throughout the study up to approximately 2 years) (del registro, en inglés)
Qué se prueba
El estudio evalua la eficacia y seguridad de lorigerlimab en aproximadamente 80 participantes con cancer de ovario resistente al platino o cancer ginecologico de celulas claras.
Lo que dice el documentoApproximately 80 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle.
Traducción automática (claude-sonnet-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroStudy CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effects, withdrawal of consent by the participant, or the study ends. Participants will be monitored closely for side effects by physical exam and routine laboratory tests every cycle. Tumor status will be checked approximately every 9 weeks for the first year, then every 12 weeks for the duration of treatment. Participants will have a safety followup performed within 30 days after treatment discontinuation. Participants who discontinue study treatment for reasons other than progression of cancer, will continue CA-125 and tumor assessments every 12 weeks. Participants who discontinue study treatment for progression of cancer will enter the 6-month survival follow up portion of the study.
Más ensayos de MGNX
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| MGC028 | Fase 1 | Reclutando pacientes | nov 2026 (prevista) |
| MGD024 | Fase 1 | En marcha, sin reclutar | nov 2026 (prevista) |
| MGC026 Dose Escalation | Fase 1 | Reclutando pacientes | may 2028 (prevista) |
| MGC030 | Fase 1 | Aún sin reclutar | sep 2028 (prevista) |
| lorigerlimab | Fase 2 | Completado | feb 2026 (real) |
| vobramitamab duocarmazine | Fase 1 | Completado | jun 2025 (real) |
Todos los de MGNX, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06730347), actualizada en may 2026.